QIAGEN N.V. (QGEN) stock
Close on Nov 12, 2026Market cap $10.87BP/E 25.8Yield 0.50%
QIAGEN N.V. grew revenue 5.7% to $2.09B over fiscal 2025. Operating income rose 376.8% to $465.85M, moving the operating margin from 4.9% to 22.3%. Free cash flow was $453.28M, down 10.5% from a year earlier. At the latest close the market valued the company at $10.87B, 25.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $10.87B
- P/E ratio
- 25.8
- Price to sales
- 5.20
- Price to book
- 2.88
- Dividend yield
- 0.50%
- Free cash flow yield
- 4.17%
Fundamentals
- Revenue
- $2.09B
- Net income
- $424.88M
- EPS, diluted
- $1.94
- Free cash flow
- $453.28M
Trading
- Previous close
- $50.30
- Open
- $50.30
- Day's range
- $50.01 – $50.31
- Volume
- 4,241,040
- Average volume (20 days)
- 6,745,182
- Beta (5 years)
- 0.68
- 52-week range
- $32.53 – $57.81
- RSI (14 days)
- 63.3
- Volatility (1 year)
- 35.4%
- Relative volume
- 1.20×
- WACC
- 7.8%
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | QGEN | S&P 500 | Difference | QGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.6% | -2.7% | +13.3 pts | ||
| 3 months | +16.5% | -1.7% | +18.3 pts | ||
| Year to date | +6.8% | +11.9% | −5.1 pts | ||
| 1 year | +7.8% | +12.0% | −4.1 pts | ||
| 3 years | +30.7% | +78.2% | −47.5 pts | +9.3% | +21.2% |
| 5 years | -7.6% | +73.2% | −80.8 pts | -1.6% | +11.6% |
| 10 years | +88.3% | +309.6% | −221.4 pts | +6.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Qiagen filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Qiagen
Biological Products, (No Diagnostic Substances)
QIAGEN provides sample and assay technologies that isolate, purify, and analyze biological materials to deliver molecular insights. The company supplies consumable products and automated instruments across key solution areas, including sample technologies, diagnostic solutions, PCR nucleic acid amplification, and genomics or next-generation sequencing. These offerings support customers across academic research, pharmaceutical development, biotechnology sectors, and clinical diagnostic laboratories.
Company profile, executives and historyQiagen stock: common questions
What is Qiagen's stock price?
QGEN closed at $50.10 on Nov 12, 2026, down 0.40% on the day. Over the past 52 weeks it traded between $32.53 and $57.81.
What is Qiagen's market cap?
Qiagen was worth $10.87B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is QGEN's P/E ratio?
QGEN trades at 25.8 times earnings, based on diluted earnings per share of $1.94 over fiscal 2025.
How much revenue does Qiagen make?
Qiagen reported revenue of $2.09B for fiscal 2025, up 5.7% from a year earlier.
Does Qiagen pay a dividend?
Yes. Qiagen paid $0.25 per share over the last twelve months, a yield of 0.50% at the latest price.
How has QGEN stock performed over the past year?
Including dividends, QGEN returned +7.8% over the past year, against +12.0% for the S&P 500.
How many QGEN shares are sold short?
6M shares were sold short at the latest FINRA report, 2.95% of the float, or 1.0 days of average trading volume.
Who are Qiagen's competitors?
Companies most similar to Qiagen by business, industry and size include TECH, RGEN, QDEL, BNTX, MRNA.
See a number that looks wrong?